Check-Cap (Check-Cap) FCF Margin % : 0.00% (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Check-Cap FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Check-Cap's Free Cash Flow for the three months ended in Dec. 2023 was $-3.54 Mil. Check-Cap's Revenue for the three months ended in Dec. 2023 was $0.00 Mil. Therefore, Check-Cap's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.

As of today, Check-Cap's current FCF Yield % is -133.61%.

The historical rank and industry rank for Check-Cap's FCF Margin % or its related term are showing as below:

CHEK's FCF Margin % is not ranked ^*
in the Medical Diagnostics & Research industry.
Industry Median: -10.815
* Ranked among companies with meaningful FCF Margin % only.

Check-Cap FCF Margin % Historical Data

The historical data trend for Check-Cap's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Check-Cap FCF Margin % Chart

Check-Cap Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

Check-Cap Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Check-Cap's FCF Margin %

For the Diagnostics & Research subindustry, Check-Cap's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Check-Cap's FCF Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Check-Cap's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Check-Cap's FCF Margin % falls into.

Check-Cap FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Check-Cap's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-17.037	/	0
	=	%

Check-Cap's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-3.539	/	0
	=	%

Check-Cap FCF Margin % Related Terms

Thank you for viewing the detailed overview of Check-Cap's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Check-Cap (Check-Cap) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Check-Cap Ltd (NAS:CHEK) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

7CC:Germany

Address

29 Abba Hushi Avenue, Check-Cap Building, P.O. Box 1271, Isfiya, ISR, 3009000

Website

https://www.check-cap.com

Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.